Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 9675651
Method for increasing performance of offspring
granted -
US 9676846
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
granted -
US 9676858
Human bispecific EGFRvIII antibody and CD3 engaging molecules
granted -
US 9676788
Aza-epoxy-guaiane derivatives and treatment of cancer
granted -
US 9675684
Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome
granted -
US 9676771
Compounds for inhibiting drug-resistant strains of HIV-1 integrase
granted -
US 9669004
Daidzein analogs as treatment for cancer
granted -
US 9670549
Gene expression signatures of neoplasm responsiveness to therapy
granted -
US 9663521
Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
granted -
US 9662306
Compositions and methods for diagnosis and treatment of metabolic syndrome
granted -
US 9663485
Tocopherol and tocopheryl quinone derivatives as correctors of Lysosomal Storage Disorders
granted -
US 9657269
Regulatory B cells (tBREGS) and their use
granted -
US 9657096
Human domain antibodies against components of the human insulin-like growth factor (IGF) system
granted -
US 9657066
Pseudomonas exotoxin A with less immunogenic B cell epitopes
granted -
US 9657292
Compositions and methods for treating or preventing lupus
granted -
US 9655366
Volatile blends and the effects thereof on the navel orangeworm moth
granted -
US 9649343
Compositions and methods for transplantation of colon microbiota
granted -
US 9650422
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
granted -
US 9650352
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
granted -
US 9649339
LAT adapter molecule for enhanced T-cell signaling and method of use
granted -
US 9651462
Method and system for sampling and separating submicron-sized particles based on density and/or size to detect the presence of a particular agent
granted -
US 9645147
Recombinant polypeptide construct comprising Plasmodium falciparum circumsporozoite protein HLA class I restricted T-cell epitopes
granted -
US 9642391
Anti-regurgitation composition maintaining gut motility
granted -
US 9644216
Adeno-associated virus vectors for treatment of glycogen storage disease
granted -
US 9644179
Use of PDL1 expressing cells to convert T cells into regulatory T cells
granted -
US 9631192
Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
granted -
US 9629816
Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same
granted -
US 9629897
Methods of producing and using regulatory B-cells
granted -
US 9629899
Targeted cargo protein combination therapy
granted -
US 9624306
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
granted -
US 9624156
Compounds and methods for delivery of prostacyclin analogs
granted -
US 9623020
Thio compounds
granted -
US 9623097
Yeast-brachyury immunotherapeutic compositions
granted -
US 9624475
Genetically stable live attenuated respiratory syncytial virus vaccine and its production
granted -
US 9616139
Conjugating amines
granted -
US 9616116
Detoxified endotoxin immunogenic compositions and uses thereof
granted -
US 9616073
Method for on-demand contraception
granted -
US 9617526
Mutated organophosphorus acid anhydrolases and their uses thereof
granted -
US 9617229
Phenylmorpholines and analogues thereof
granted -
US 9610338
Serologic correlates of protection against bacillus anthracis infection
granted -
US 9604901
Process to prepare treprostinil, the active ingredient in Remodulin®
granted -
US 9605044
Methods and compositions for modulating immune tolerance
granted -
US 9598492
Human monoclonal antibodies specific for CD22
granted -
US 9598471
Bacteriocin with novel activity
granted -
US 9598703
Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
granted -
US 9598441
Therapeutic compounds and methods
granted -
US 9592304
Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
granted -
US 9592207
Intranasal administration of ketamine to treat depression
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory